Alba Therapeutics Announces Phase IIb Clinical Trial For Oral AT-1001 For The Treatment Of Celiac Disease
Sep 20th 2007Drug InformationGastroIntestinal / Gastroentorology
Alba Therapeutics Corporation today announced that it has dosed its first patient in a six-week Phase IIb trial with oral AT-1001, an inhibitor of gastrointestinal barrier dysfunction, for the maintenance of remission in patients with Celiac Disease (CD). [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
